Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
AI-model voorspelt risico op huidkanker beter dan bestaande methoden
mrt 2024 | Dermato-oncologie